14 gene sets were associated with known behavioural, metabolic, and molecular effects of sGC treatment (Table 1; NES > 1.6, FDR < 0.25), including type II diabetes mellitus (Fig. 7B; NES > 1.6, FDR < 0.25). The gene discussed is SGCB; the disease is type 2 diabetes mellitus.